学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

鈴木仁（スズキヒトシ）

研究テーマ	腎臓内科
研究業績（論文）	英文原著 1. Suzuki H, Kurusu A, Hishiki T, Funabiki K, Shirato I, Tomino Y: A cese of IgA nephropathy with a long history (32 years) in relatively poor prognosis group. Hong Kong J Nephrol 5: 44-49, 2003 2. Tomino Y, Suzuki H, Horikoshi S, Imai E, Miyazaki M, Ohzono Y, Harada T, Yoshida H, Kawamura T, Kobayashi Y, Suzuki S, Nitta K, Hotta O, Yoshikawa N, Endoh M and Sakai H: Multicenter trial of adrenocorticosteroids in Japanese patients with IgA nephropathy-results of the special study group (IgA nephropathy) on progressive glomerular disease, Ministry of Health, Labor and Walfare of Japan. Current Topics in Steroid Research 4: 93-98, 2004 3. Suzuki H, Suzuki Y, Yamanaka T, Hirose S, Toei J, NIshimura H, Horikoshi S, Tomino Y: Genome-wide scan in novel IgA nephropathy model identifies susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23. J Am Soc Nephrol 16: 1289-99, 2005 4. Moore JS, Kulhavy R, Tomana M, Moldoveanu Z, Suzuki H, Brown R, Hall S, Kilian M, Poulsen K, Mestecky J, Julian BA, Novak J: Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol 44: 2598-2604, 2007 5. Raska M, Moldoveanu Z, Suzuki H, Brown R, Kulhavy R, Andrasi J, Hall S, Vu HL, Carlsson F, Lindahl G, Tomana M, Julian BA, Wyatt RJ, Mestecky J, Novak J: Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells. J Mol Biol 369: 69-78, 2007 6. Suzuki H, Suzuki Y, Aizawa M, Yamanaka T, Kihara M, Pang H, Horikoshi S, Tomino Y: Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int 72: 319-327, 2007 7. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcón GS, Kimberly RP, Tomino Y, Mestecky J, Novak J: IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly-glycosylated IgA1. J Clin Invest 118: 629-639, 2008 8. Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, Renfrow MB, Novak L, Wyatt RJ, Novak J: Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 31: 29-37, 2008 9. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, Kanou T, Tsukaguchi H, Novak J, Horikoshi S, Tomino Y: Toll-Like Receptor 9 Affects Severity of IgA Nephropathy. J Am Soc Nephrol 19: 2384-2395, 2008 10. Julian BA, Suzuki H, Spasovski G, Suzuki Y, Tomino Y, Novak J: Application of proteomic analysis to renal disease in the clinic. Proteomics Clin Appl 3: 1023-1028, 2009 11. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668-1677, 2009 12. Mischak H, Kolch W, Aivaliotis M, Bouyssié D, Court M, Dihazi H, Dihazi GH, Franke J, Garin J, Anne Gonzalez de Peredo5,6, Iphöfer A, Jänsch L, Lacroix C, Makridakis M, Masselon C, Metzger J, Monsarrat B, Mrug M, Norling M, Novak J, Pich A, Pitt A, Bongcam-Rudloff E, Siwy J, Suzuki H, Thongboonkerd V, Wang LS, Zoidakis J, Zürbig P, Schanstra JP, Vlahou A: Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 4: 464-478, 2010 13. Hu SL, Colvin GA, Rifai A, Suzuki H, Novak J, Esparza A, Farooqi S, Julian BA: Glomerulonephritis after Hematopoietic Cell Transplantation: IgA Nephropathy with Increased Excretion of Galactose-deficient-IgA1. Nephrol Dial Transplant 25: 1708-1713, 2010 14. Gomes MM, Suzuki H, Brooks MT, Tomana M, Moldoveanu Z, Mestecky J, Julian BA, Novak J, Herr AB: Recognition of Galactose-Deficient O-Glycans in the Hinge Region of IgA1 by N-Acetylgalactosamine-Specific Snail Lectins: A Comparative Binding Study. Biochemistry 13: 5671-5682, 2010 15. Takahashi K, Wall SB, Suzuki H, Smith AD, Hall S, Paulsen K, Kilian M, Mobley JA, Julian BA, Mestecky J, Novak J, Renfrow MB: Clustered O-glycans of IgA1: Defining macro- and micro-heterogeneity by use of electron capture/transfer dissociation. Mol Cell Proteomics 9: 2545-2557, 2010 16. Lindfors K, Suzuki H, Novak J, Collin P, Saavalainen P, Koskinen L, Maki M, Kaukinen K: Galactosylation of serum IgA1 O-glycan in celiac disease. J Clin Immunol 31: 74-79, 2010 17. Kiryluk K, Moldoveanu Z, Sanders JT, Elison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ: Aberrant Glycosylation of IgA1 is Inherited in Pediatric IgA Nephropathy and Henoch-Schönlein Purpura Nephritis. Kidney Int 80: 79-87, 2011 18. Tomino Y, Shimizu Y, Hamada C, Kurusu A, Ohsawa I, Suzuki Y, Tsuge T, Io H, Kobayashi N, Takeda Y, Asanuma K, Tanaka Y, Suzuki H, Nakata J, Takara K, Horikoshi S: One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease. J Nephrol 24: 756-763, 2011 19. Kajiyama T, Suzuki Y, Kihara M, Suzuki H, Horikoshi S, Tomino Y: Different pathological roles of Toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy. Clin Devl Immunol, 2011:819646, 2011 20. Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, Tomino Y: Pathological role of tonsillar B cells in IgA nephropathy. Clin Devl Immunol, 2011:639074, 2011 21. Camilla R, Suzuki H, Daprà V, Loiacono E, Peruzzi L, Amore A, Ghiggeri GM, Mazzucco G, Scolari F, Gharavi AG, Appel GB, Troyanov S, Novak J, Julian BA, Coppo R. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 6: 1903-11, 2011 22. Novak J, Kafkova LR, Suzuki H, Tomana M, Matousovic K, Brown R, Stacy Hall, Sanders JT, Eison TM, Moldoveanu Z, Novak L, Novak Z, Mayne R, Julian BA, Mestecky J, Wyatt RJ: IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant,26: 3451-3457, 2011 23. Suzuki Y, Suzuki H, Sato D, Kajiyama T, Okazaki K, Hashimoto A, Kihara M, Yamaji K, Satake K, Nakata J, Aizawa M, Novak J, Tomino Y: Reevaluation of the mucosa-bone marrow axis in IgA nephropathy with animal models. Adv Otorhinolaryngol 72: 64-7, 2011 24. Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Mestecky J, Suzuki H: Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol 72: 60-3, 2011 25. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795-1803, 2011 26. Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, Horikoshi S, Ikeda K, Tomino Y: Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant 27: 1090-7, 2012 27. Okazaki K, Suzuki Y, Otsuji M, Suzuki H, Kihara M, Kajiyama T, Hashimoto A, Nishimura H, Brown R, Hall S, Novak J, Izui S, Hirose S, Tomino Y: Development of a Model of Early-Onset IgA Nephropathy. J Am Soc Nephrol 23: 1364-1374, 2012 28. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J: Serum autoantibodies specific for galactose-deficient IgA1 associate with disease progression in IgA nephropathy. J Am Soc Nephrol 23: 1579-1587, 2012 29. Hashimoto A, Suzuki Y, Suzuki H, Ohsawa I, Brown R, Hall S, Tanaka Y, Novak J, Ohi H, Tomino Y: Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am J Pathol 181: 1338-1347, 2012 30. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG: Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genet 8: e1002765, 2012 31. Schoeb TR, Jarmi T, Hicks MJ, Henke S, Zarjou A, Suzuki H, Kramer P, Novak J, Agarwal A, Bullard DC: Endothelial nitric oxide synthase inhibits the development of autoimmune-mediated vasculitis in mice. Arthritis Rheum 64: 4114-4124, 2012 32. Nakata J, Ohsawa I, Onda K, Tanimoto M, Kusaba G, Takeda Y, Kobayashi N, Asanuma K, Tanaka Y, Sato M, Inami Y, Suzuki H, Suzuki H, Masuda A, Nonaka K, Sasaki Y, Hisada A, Hamada C, Horikoshi S, Tomino Y. Risk of overestimation of kidney function using GFR-estimating equations in patients with low inulin clearance. J Clin Lab Anal 26: 248-53, 2012 33. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Horikoshi S, Novak J, Tomino Y: Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. Nephrol Dial Transplant 28: 320-326, 2013 34. Hastings MC, Moldoveanu Z, Suzuki H, Berthoux F, Julian BA, Sanders JT, Renfrow MB, Novak J, Wyatt RJ: Biomarkers in IgA Nephropathy: Relationship to Pathogenetic Hits. Expert Opin Med Diagn 7: 615-627, 2013 35. Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 18: 481-6, 2014. doi: 10.1007/s10157-013-0849-x. 36. Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol.18: 770-777, 2014. doi: 10.1007/s10157-013-0921-6. 37. Maiguma M, Suzuki Y, Suzuki H, Okazaki K, Aizawa M, Muto M, Tomino Y. Dietary zinc is a key environmental modifier in the progression of IgA nephropathy. PLoS One 28, e90558, 2014. doi: 10.1371/journal.pone.0090558. 38. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuzaki K, Horikoshi S, Novak J, Tomino Y. Changes in Nephritogenic Serum Galactose-Deficient IgA1 in IgA Nephropathy following Tonsillectomy and Steroid Therapy. PLoS One 21, e89707, 2014. doi: 10.1371/journal.pone.0089707. 39. Aizawa M, Suzuki Y, Suzuki H, Pang H, Kihara M, Nakata J, Yamaji K, Horikoshi S, Tomino Y. Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy. PLoS One 17: e95365, 2014. doi: 10.1371/journal.pone.0095365. 40. Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 23: e98081, 2014. doi: 10.1371/journal.pone.0098081. 41. Satake K, Shimizu Y, Sasaki Y, Yanagawa H, Suzuki H, Suzuki Y, Horikoshi S, Honda S, Shibuya K, Shibuya A, Tomino Y. Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy. BMC Nephrol. 2014 Jun 13;15:89. doi: 10.1186/1471-2369-15-89 42. Kiryluk K, Suzuki H, Gharavi A et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187-96, 2014. doi: 10.1038/ng.3118. (92, 77) 43. Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, Tomino Y, Gharavi AG, Novak J. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem 21: 5330-9, 2014. doi: 10.1074/jbc.M113.512277. 44. Suzuki Y, Suzuki H, Makita Y, Takahata A, Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H, Okazaki K, Tomino Y. Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers. Int J Nephrol Renovasc Dis 7: 409-14, 2014. doi: 10.2147/IJNRD.S50513. 45. Suzuki H, Suzuki Y, Novak J, Tomino Y. Development of Animal Models of Human IgA Nephropathy. Drug Discov Today: Dis Model, 11: 5-11, 2014. doi:10.1016/j.ddmod.2014.07.002 46. Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y. The kinetics of glomerular deposition of nephritogenic IgA. PLoS One 9: e113005, 2014. doi: 10.1371/journal.pone.0113005. IF:2.766 47. Kim YG, Alvarez M, Suzuki H, Hirose S, Izui S, Tomino Y, Huard B, Suzuki Y. Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS One 10: e0137044, 2015. doi: 10.1371/journal.pone.0137044. IF:2.766 48. Stuchlova Horynova M, Vrablikova A, Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian BA, Renfrow MB, Novak J, Raska M. N-Acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Nephrol Dial Transplant 30: 234-8, 2015. doi: 10.1093/ndt/gfu308. IF:4.47, CI:6 49. Suzuki Y, Suzuki H, Yasutake J, Tomino Y. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting. Expert Opin Biol Ther 15: 583-93, 2015. doi: 10.1517/14712598.2015. 50. Novak J, Rizk D, Takahashi K, Zhang XW, Bian Q, Ueda H, Ueda Y, Reily C, Lai LY, Hao C, Novak L, Huang ZQ, Renfrow MB, Suzuki H, Julian BA. New Insights into the Pathogenesis of IgA Nephropathy. Kidney Dis 1: 8-18, 2015. DOI:10.1159/000382134 51. Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, Kaneko E, Tomino Y. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 30: 1315-21, 2015 doi: 10.1093/ndt/gfv221. IF:4.47, CI:6 52. Diciolla M, Binetti G, Noia TD, Pesce F, Schena FP, Vagane AN, Bjorneklett R, Suzuki H, Tomino Y, Naso D: Patient Classification and Outcome Prediction in IgA Nephropathy. Computers in Biology and Medicine 66: 278-286, 2015 IF:1.836,CI:2 53. Pesce F, Diciolla M, Binetti G, Naso D, Ostuni VC, Di Noia T, Vågane AM, Bjørneklett R, Suzuki H, Tomino Y, Di Sciascio E, Schena FP. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrol Dial Transplant. 31: 80-6, 2016 doi: 10.1093/ndt/gfv232 IF:4.47, CI:2 54. Yamanaka T, Tamauchi H, Suzuki Y, Suzuki H, Horikoshi S, Terashima M, Iwabuchi K, Habu S, Okumura K, Tomino Y. Release from Th1-type immune tolerance in spleen and enhanced production of IL-5 in Peyer's patch by cholera toxin B induce the glomerular deposition of IgA. Immunobiology 221: 577-85, 2016. doi: 10.1016/j.imbio.2015.12.001 IF:2.72, CI:0 55. Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, Crowley MR, Hargett A, Zhang Z, Suzuki H, Hall S, Wyatt RJ, Julian BA, Renfrow MB, Gharavi AG, Novak J. Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy. J Am Soc Nephrol 27: 3278-3284, 2016 10.1681/ASN.2014101044 IF:8.966, CI:4 56. Matsuzaki K, Suzuki H, Kobayashi T, Shimizu Y, Tomino Y. Analysis of Predictive Factors for Deterioration of Renal Function in Chronic Kidney Disease Patients. J Nephrol Ther 6: 240, 2016. doi: 10.4172/2161-0959.1000240 IF:0, CI:0 57. Kato TS, Nakamura H, Murata M, Kuroda K, Suzuki H, Yokoyama Y, Shimada A, Matsushita S, Yamamoto T, Amano A. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery. BMC Cardiovasc Disord 13 : 181-189, 2016 doi: 10.1186/s12872-016-0341-0 IF:1.832, CI:0 58. Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z, Wyatt RJ, Novak J, Julian BA. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? Dis Markers 2016. doi: 10.1155/2016/7806438. IF:2.348,CI:1 59. Maruyama S, Gohda T, Suzuki Y, Suzuki H, Sonoda Y, Ichikawa S, Li Z, Murakoshi M, Horikoshi S, Tomino Y. Beneficial effects of tonsillectomy plus steroid pulse therapy on inflammatory and tubular markers in patients with IgA nephropathy. Kidney Res Clin Pract 35: 233-236, 2016 doi: 10.1016/j.krcp.2016.09.002 IF:0, CI:1 60. Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakai S, Righini C, Maiguma M, Izui S, Tomino Y, Huard B, Suzuki Y. Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy. J Am Soc Nephrol 28: 1227-1238, 2017 doi: 10.1681/ASN.2016050496 IF:8.966, CI:3 61. Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J. GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 10: e1006609, 2017 doi: 10.1371/journal.pgen.1006609 62. Berthoux F, Suzuki H, Mohey H, Maillard N, Mariat C, Novak J, Julian BA. Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation. J Am Soc Nephrol 28: 1943-1950, 2017 doi: 10.1681/ASN.2016060670 63. Suzuki H, Kihara M, Mano S, Kobayashi T, Kanaguchi Y, Hidaka T, Gohda T, Suzuki Y: Efficacy and Safety of Denosumab for the Treatment of Osteoporosis in Patients with Chronic Kidney Disease. J Clin Exp Nephrol 2: 1-5, 2017, DOI: 10.21767/2472-5056.100030 64. Murakoshi M, Gohda T, Sonoda Y, Suzuki H, Tomino Y, Horikoshi S, Suzuki Y: Effect of tonsillectomy with steroid pulse therapy on circulating tumor necrosis factor receptors 1 and 2 in IgA nephropathy. Clin Exp Nephrol 21: 1068-1074, 2017 doi: 10.1007/s10157-017-1408-7 65. Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z, Kiryluk K, Suzuki Y, Wyatt RJ, Tomino Y, Gharavi AG, Weinmann A, Julian BA, Willey CD, Novak J. Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. Kidney Int Rep 19: 1194-1207, 2017. doi: 10.1016/j.ekir.2017.07.002 66. Placzek W, Yanagawa H, Makita Y, Renfrow MB, Julian BA, Rizk DV, Suzuki Y, Novak J, Suzuki H: Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. Plos One 11: e0190967, 2018. doi: 10.1371/journal.pone.01909672018, IF:2.766 67. Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamazaki K, Sofue T, Kano T, Suzuki Y: IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1 oriented pathogenesis Kidney Int 93: 700-705, 2018, IF:8.429 68. Suzuki H, Suzuki Y: Murine model of human IgA nephropathy. Seminar in Nephrol 38: 513-520, 2018, IF:3.35 69. Suzuki H: Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol 23: 26-31, 2018. doi: 10.1007/s10157-018-1582-2, IF:2.016, 70. Honda D, Ohsawa I, Shimizu Y, Maiguma M, Hidaka T, Suzuki H, Io H, Mano S, Takahara H, Rinno H, Tomino Y, Suzuki Y: A case of suffocation by an acute airway edema in a patient with hereditary angioedema invoking the need for urgent improvements of treatment availability in Japan. Intern Med 57: 3193-3197, 2018.　 doi: 10.2169/internalmedicine.9262-17, IF:0.817 71. Gohda T, Suzuki H, Hidaka T, Ueda S, Suzuki Y: An update of pathogenesis and treatment of major chronic kidney diseases. Juntendo Medical Journal 64:227-234, 2018 72. Sofue T, Suzuki H, Ueda N, Kushida Y, Minamino T: Post-transplant immunoglobulin A deposition and nephropathy in allografts. Nephrology 23: 4-9, 2018, IF:2.178 73. Yamazaki K, Suzuki H, Yasutake J, Yamazaki Y: Galactose-deficient IgA1 specific antibody recognizes GalNAc modified unique epitope on hinge region of IgA1. Monoclon Antib Immunodiagn Immunother 37: 252-256, 2018 74. Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG: A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int 19: 30174-7, 2019 75. Suzuki H: Multi-hit pathogenesis of IgA nephropathy. Juntendo Medical Journal 65: 537-542, 2019 76. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y: TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int 97: 340-349, 2020 77. Koshida T, Wu S, Suzuki H, Wanchoo R, Bijol V, Tomita S, Suzuki Y, Jhaveri K: Thrombotic Microangiopathy in Dasatinib-treated patients with Chronic Myeloid Leukemia. Journal of Onco-Nephrology, 2019 in press. 78. Suzuki H, Moldoveanu Z, Julian BA, Wyatt RJ, Novak J: Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int Rep 30: 1717-1724, 2019 79. Murayama G, Chiba A, Suzuki H, Nomura A, Mizuno T, Kuga T, Nakamura S, Amano H, Hirose S, Yamaji K, Suzuki Y, Tamura N, Miyake S: Critical role for mucosal-associated invariant T cells as regulators and therapeutic targets in systemic lupus erythematosus. Frontiers in Immunology 29: 10: 2681, 2019 80. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y: TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int 97: 340-349, 2020 81. Yamada K, Huang Z, Raska M, Reily C, Anderson J, Suzuki H, Kiryluk K, Gharavi AG, Julian BA, Willey CD, Novak J: Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy. Kidney Dis (Basel), 6: 168-180, 2020 82. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, Cui Z, Lin L, Hu X, Yu X, Xu J, Liu G, Caliskan Y, Sidore C, Balderes O, Rosen RJ, Bodria M, Zanoni F, Zhang JY, Krithivasan P, Mehl K, Marasa M, Khan A, Ozay F, Canetta PA, Bomback AS, Appel GB, Sanna-Cherchi S, Sampson MG, Mariani LH, Perkowska-Ptasinska A, Durlik M, Mucha K, Moszczuk B, Foroncewicz B, Pączek L, Habura I, Ars E, Ballarin J, Mani LY, Vogt B, Ozturk S, Yildiz A, Seyahi N, Arikan H, Koc M, Basturk T, Karahan G, Akgul SU, Sever MS, Zhang D, Santoro D, Bonomini M, Londrino F, Gesualdo L, Reiterova J, Tesar V, Izzi C, Savoldi S, Spotti D, Marcantoni C, Messa P, Galliani M, Roccatello D, Granata S, Zaza G, Lugani F, Ghiggeri G, Pisani I, Allegri L, Sprangers B, Park JH, Cho B, Kim YS, Kim DK, Suzuki H, Amoroso A, Cattran DC, Fervenza FC, Pani A, Hamilton P, Harris S, Gupta S, Cheshire C, Dufek S, Issler N, Pepper RJ, Connolly J, Powis S, Bockenhauer D, Stanescu HC, Ashman N, Loos RJF, Kenny EE, Wuttke M, Eckardt KU, Köttgen A, Hofstra JM, Coenen MJH, Kiemeney LA, Akilesh S, Kretzler M, Beck LH, Stengel B, Debiec H, Ronco P, Wetzels JFM, Zoledziewska M, Cucca F, Ionita-Laza I, Lee H, Hoxha E, Stahl RAK, Brenchley P, Scolari F, Zhao MH, Gharavi AG, Kleta R, Chen N, Kiryluk K: The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications 11: 1600, 2020. 83. Shirai Y, Miura K, Yabuuchi T, Nagasawa T, Ishizuka K, Takahashi K, Taneda S, Honda K, Yamaguchi Y, Suzuki H, Suzuki Y, Hattori M: Rapid progression to end-stage renal disease in a child with IgA-dominant infection-related glomerulonephritis associated with parvovirus B19. CEN Case Reports 9:423-430, 2020 84. Kubo A, Hidaka T, Nakayama M, Sasaki Y, Takagi M, Suzuki H, Suzuki Y: Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases. BMC Nephrol 18: 402, 2020 85. Takahata A, Arai S, Hiramoto E, Kitada K, Kato R, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y: Crucial Role of AIM/CD5L in the Development of Glomerular Inflammation in IgA Nephropathy. J Am Soc Nephrol 31: 2013-2024, 2020 86. Wada T, Hara A, Muso E, Maruyama S, Kato S, Furuichi K, Yoshimura K, Toyama T, Sakai N, Suzuki H, Tsukamoto T, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Goto S, Sakamaki Y, Yokoyama H, Mori N, Tanaka S, Yuzawa Y, Hasegawa M, Matsubara T, Wada J, Tanabe K, Masutani K, Abe Y, Tsuruya K, Fujimoto S, Iwatsubo S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Sofue T, Miyata H, Nakano T, Ohtake T, Kobayashi S; LICENSE study Group.: Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia. Clin Exp Nephrol 25: 1-8, 2021 87. Han W, Suzuki S, Watanabe S, Nakata M, Ichikawa D, Koike J, Oda T, Suzuki H, Suzuki Y, Shibagaki Y: Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis: A case report. Medicine 100: e24460, 2021 88. Lee M, Suzuki H, Kato R, Fukao Y, Nakayama M, Kano T, Makita Y, Suzuki Y: Renal pathological analysis using galactose deficient IgA1-specific monoclonal antibody is a strong tool for differentiation primary IgA nephropathy from secondary IgA nephropathy. CEN Case Reports 10: 17-22, 2021 89. Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N, Huang ZQ, Knoppova B, Khan A, Hall S, Yanagawa H, Brown R, Winstead CJ, O’Quinn DB, Weinmann A, Gharavi AG, Kiryluk K, Julian BA, Weaver CT, Suzuki Y, Novak J: Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J Autoimmune 118: 102593, 2021　 89. Kano T, Suzuki H, Makita Y, Fukao Y, Suzuki Y: Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. Kidney Int 100: 364-376, 2021 doi: 10.1016/j.kint.2021.04.026. IF: 8.945, CI:N/D 90. Matsuzaki K, Suzuki H, Kawamura T, Tomino Y, Suzuki Y: Utility of remission criteria for the renal prognosis of IgA nephropathy. Clin Exp Nephrol 25: 988-995, 2021. doi: 10.1007/s10157-021-02069-w. IF:1.854, CI:N/D 91. Suzuki Y, Monteiro R, Coppo R, Suzuki H: The phenotypic difference of IgA nephropathy and its race/gender-dependent molecular mechanisms. Kidney 360 2:1339-1348, 2021 92. Akira M, Suzuki H, Ikeda A, Iwasaki M, Honda D, Takahara H, Rinno H, Tomita S, Suzuki Y: Atypical histological abnormalities in an adult patient with nephronophthisis harboring NPHP1 deletion: a case report. BMC Nephrol 22: 261, 2021 doi: 10.1186/s12882-021-02466-z 93. Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I, Sugiyama H, Fujimoto S, Miura K, Matsumura C, Goto Y, Suzuki H, Kuroki A, Yoshino A, Nakatani S, Hiromura K, Yamamoto R, Yokoyama H, Narita I, Isaka Y: Demographic, Clinical Characteristics and Treatment Outcomes of Immune-Complex Membranoproliferative Glomerulonephritis and C3 Glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. Plos One 16: e0257397, 2021. doi: 10.1371/journal.pone.0257397 94. Suzuki H, Kikuchi M, Koike K, Komatsu H, Matsuzaki K, Takahashi K, Ichikawa D, Okabe M, Obata Y, Katafuchi R, Kihara M, Kohatsu K, Sasaki T, Shimizu A, Nakanishi K, Fukuda A, Miyazaki Y, Muto M, Yanagawa H, Suzuki Y, Fujimoto S, Furuichi K, Okada H, Narita I: A digest from evidence based clinical practice guideline for IgA nephropathy 2020. Clin Exp Nephrol, 25: 1269-1276, 2021. IF:1.77　 10.1007/s10157-021-02095-8. 95. Suzuki H, Novak J: IgA glycosylation and immune complex formation in IgA nephropathy. Semin Immunopathol, 43: 669-678, 2021 IF:7.48, CI:N/D, 10.1007/s00281-021-00883-8 96. Murakami Y, Fukui R, Tanaka R, Motoi Y, Kanno A, Sato R, Yamaguchi K, Amano H, Furukawa Y, Suzuki H, Suzuki Y, Tamura N, Yamashita N, Miyake K: Anti-TLR7 antibody protects against lupus nephritis in NZBWF1 mice by targeting B cells and patrolling monocytes. Frontiers in Immunology, 12:777197, 2021. IF:5.085 97. Hara A, Wada T, Eri Muso, Maruyama S, Kato S, Furuichi K, Yoshimura K, Toyama T, Sakai N, Suzuki H, Tsukamoto T, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Goto S, Sakamaki Y, Yokoyama H, Mori N, Tanaka S, Yuzawa Y, Hasegawa M, Matsubara T, Wada J, Tanabe K, Masutani K, Abe Y, Tsuruya K, Fujimoto S, Iwatsubo S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Sofue T, Miyata H, Nakano T, Ohtake T, Kobayashi S: Long-term effects of low-density lipoprotein apheresis on diabetic patients with severe proteinuria and hypercholesterolemia: A multicenter prospective study. Renal Replacement Therapy, in press 98. Matsuzaki K, Aoki R, Nihei Y, Suzuki H, Kihara M, Yokoo T, Kashihara N, Narita I and Suzuki Y. Gross Hematuria after SARS-CoV-2 Vaccination: Questionnaire Survey in Japan. Clin Exp Nephrol,29: 1-2, 2021. IF:1.77 99. Ishida M, Matsuzaki K, Ikai H, Suzuki H, Kawamura T, Suzuki Y: Cost analysis of screening for IgA nephropathy using novel biomarkers. Value Health Reg Issues, 29:8-15, 2022 100. Nihei Y, Kishi M, Suzuki H, Koizumi A, Yoshida M, Hamaguchi S, Iwasaki M, Fukuda H, Takahara H, Kihara M, Tomita S, Suzuki Y. IgA nephropathy with gross hematuria following a COVID-19 mRNA vaccination. Intern Med 61:1033-1037, 2022 101. Fukao Y, Suzuki H, Kim JS, Jeong KW, Makita Y, Kano T, Nihei Y, Nakayama M, Lee M, Kato R, Chang JM, Lee SH, Suzuki Y: Galactose-deficient IgA1 as a candidate urinary marker of IgA nephropathy. J Clin Med 11: 3173, 2022 102. Makita Y, Suzuki H, Nakano D, Yanagawa H, Kano T, Novak J, Nishiyama A, Suzuki Y: Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries. Nephrol Dial Transplant 37: 1629-1636, 2022 103. Suzuki H, Novak J: New insight into the pathogenesis and therapies of IgA nephropathy. J Clin Med 11: 4378, 2022 104. Matsuzaki K, Ohigashi T, Sozu T, Ishida M, Kobayashi D, Suzuki H, Suzuki Y, Kawamura T: Identification of high-risk groups in urinalysis: Lessons from the longitudinal analysis of annual check-ups. Healthcare 10: 1704, 2022 105. Ishida M, Matsuzaki K , Suzuki H, Suzuki Y, Kawamura T, Marunaka Y, Iwami T: Association between 3-Year Repetitive Isolated Hematuria and eGFR deterioration in an Apparently Healthy Population: A Retrospective Cohort Study. Int J Environ Res Public Health 19: 11466, 2022 106. Hara A, Wada T, Muso E, Maruyama S, Kato S, Furuichi K, Yoshimura K, Toyama T, Sakai N, Suzuki H, Tsukamoto T, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Goto S, Sakamaki Y, Yokoyama H, Mori N, Tanaka S, Yuzawa Y, Hasegawa M, Matsubara T, Wada J, Tanabe K, Masutani K, Abe Y, Tsuruya K, Fujimoto S, Iwatsubo S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Sofue T, Miyata H, Nakano T, Ohtake T, Kobayashi S; LICENSE study group: Effect of low-density lipoprotein apheresis on quality of life in patients with diabetes, proteinuria, and hypercholesterolemia. Blood Purif 15: 1-9, 2022 107. Yokote S, Ueda H, Shimizu A, Okabe M, Haruhara K, Sasaki T, Aoki R, Joh K, Saeki H, Tomita S, Tsuboi N, Suzuki H, Suzuki Y, Yokoo T: First diagnosis of IgA Nephropathy following SARS-CoV-2 mRNA Vaccination in Japan. Kidney Int Rep 19: 179-182, 2023 108. Yoshida M, Suzuki H, Hamaguchi S, Iwasaki M, Fukuda H, Takahara H, Tomita S, Suzuki Y: March hemoglobinuria progressed to acute kidney injury after kendo practice: A case report. BMC Nephrol 23: 368, 2022 109. Nakayama M, Suzuki H, Fukao Y, Lee M, Kano T, Suzuki Y: Clinical significant of intensity of glomerular galactose-deficient IgA1 deposition in IgA nephropathy. Kidney Int Rep 29: 2726-2729, 2022 110. Kiryluk K, Suzuki H, et al. Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nat Communications 13: 6859, 2022 111. Kano T, Suzuki H, Makita Y, Nihei Y, Fukao Y, Nakayama M, Lee M, Kato R, Aoki R, Yamada K, Muto M, Suzuki Y: Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy. Biomedicines 10: 3027, 2022 112. Iwasaki M, Suzuki H, Umezawa Y, Koshida T, Saito M, Fukuda H, MD, Takahara H, Matsuzaki K, Suzuki Y: Efficacy and safety of pemafibrate in patients with chronic kidney disease: a retrospective study. Medicine 102: e32818, 2023 113. Sofue T, Oguchi H, Yazawa M, Tsujita M, Futamura K, Nishihira M, Toyoda M, Kano T, Suzuki H: Serological and Histopathological Assessment of Galactose-Deficient Immunoglobulin A1 Deposition in Kidney Allografts: A Multicenter Prospective Observational Study. Plos One 18: e0281945, 2023 114. Misaki T, Naka S, Suzuki H, Lee M, Aoki R, Nagasawa Y, Matsuoka D, Ito S, Nomura R, Matsumoto-Nakano M, Suzuki Y, Nakano K: cnm -positive Streptococcus mutans is associated with galactose-deficient IgA in patients with IgA nephropathy. Plos One 18: e0282367, 2023 115. Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, Nakayama M, Suzuki H, Kikkawa M, Kazuno S, Miura Y, Suzuki Y, Kitamura D: Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv 9: eadd6734, 2023 116. Nihei Y, Suzuki H, Suzuki Y. Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy. Front Immunol 11 14: 1165394, 2023 117. Elena Sanchez-Rodriguez E, Suzuki H, Kiryluk K, et al. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet 2023 in press 118. Lee M, Suzuki H, Nihei Y, Matsuzaki K, Suzuki Y. Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management, and prognosis. CKJ 2023 in press 119. Lee M, Suzuki H, Ogiwara K, Aoki R, Kato R, Nakayama M, Fukao Y, Nihei Y, Kano T, Makita Y, Muto M, Yamada K, Suzuki Y: Nucleotide-sensing TLR9/TLR7 system is a potential therapeutic target for IgA nephropathy. Kidney Int 2023 in press 120. Matsuzaki K, Suzuki H*, Kikuchi M, Koike K, Komatsu H, Takahashi K, Narita I, Okada H: Current treatment status of IgA nephropathy in Japan: a questionnaire survey. Clin Exp Nephrol 2023 in press 和文原著 1. 加納達也、鈴木祐介、鈴木　仁、柘植俊直、堀越哲、富野康日己：Expression of Toll-like receptor in tonsils, and therapeutic outcome of tonsillectomy and steroid pulse therapy in patients with IgA nephropathy. 順天堂医学53: 97-105, 2007 2. 鈴木祐介、鈴木　仁、富野康日己：IgA腎症の発症機序 -動物モデルの解析から-. 日本腎臓学会誌50: 456-460, 2008 3. 富野康日己、浅沼克彦、井尾浩章、鈴木仁、田中裕一、中田純一郎、小林則善、武田之彦、稲見裕子、清水芳男、柘植俊直、鈴木祐介、大澤勲、来栖厚、濱田千江子、堀越哲、若林道郎、青木竜弥、金口泰彦、彰一祐：高カリウム血症を伴う慢性腎臓病（CKD）患者に対するプリスチレンスルホン酸カルシウムゼリーの長期投与効果の検討．Therapeutic Research 31: 1471-1480, 2010 4. 高良勝彦、鈴木　仁、鈴木祐介、堀越哲、富野康日己：慢性腎臓病を伴う高血圧患者に対する塩酸ベニジピンの尿蛋白改善効果作用並びに抗酸化作用 –未治療高血圧患者における層別解析研究-．順天堂医学 57: 610-616,2011 5. 中田純一郎、濱田千江子、中野貴則、佐藤大介、鈴木祐介、鈴木　仁、井尾浩章、堀越　哲、富野康日己：好酸球性腹膜炎を契機に被嚢性腹膜硬化症（EPS）を発症した長期腹膜透析患者の1例．透析会誌44: 1031-1037, 2011 6. 山初あや、濱田千江子、野中香苗、佐々木洋平、渡邉智成、石井杏理沙、牧田侑子、仲本宙高、鈴木　仁、高原久嗣、井尾浩章、金子佳代、堀越哲、室谷典義、富野康日己：回腸末端部の石灰化が進行し、腹膜透析離脱5年後に被嚢性腹膜硬化症を発症した1症例．透析会誌45: 367-373, 2012 7. 久田温子、鈴木　仁、村越真紀、波多野琢、大澤勲、堀越哲、富野康日己：急性腎障害により意識障害を呈する高マグネシウム血症を発症した一例．日本内科学会誌 101: 3513-3515, 2012 8. 松尾清一、川村哲也、鈴木祐介、城謙輔、富野康日己、堀越哲、西野友哉、吉川徳茂、服部元史、木村健二郎、安田隆、白井小百合、柴田孝則、吉村光弘、宇都宮保典、遠藤正之、坂本なほ子、松島雅人、宮崎陽一、安田宜成、横尾隆、香美祥二、幡谷浩史、鈴木　仁、松崎慶一、内田俊也、伊藤孝史、清水章、片渕律子、久野敏、橋口明典：IgA腎症の寛解基準の提唱．日本腎臓学会誌55巻7号, 1249-1254, 2013 9. 狩野俊樹、鈴木　仁、鈴木祐介：腸管粘膜免疫異常と腸腎連関．日本腎臓学会誌59, 2017, P552-556 10. 鈴木　仁、木原正夫、鈴木祐介：IgA腎症とIgA血管炎の共通病態．東京内科医会会誌 33: 169-170, 2017 11. 鈴木　仁、鈴木祐介：腎臓病学この1年の進歩　IgA腎症の病態．日本腎臓学会誌62: 26-33, 2020 12. 1鈴木祐介、鈴木　仁：IgA腎症の病因解明と治療の進歩．日本内科学会雑誌9: 2021 13. 鈴木　仁、鈴木祐介：IgA腎症の免疫異常．日本腎臓学会誌63:250-256, 2021 和文著書 1. 鈴木　仁、白土　公：紫斑病性腎炎．EBMに基づく臨床データブック, 中外医学社東京, vol.27: 528-529, 2001 2. 鈴木　仁、山下倫史、高原久嗣、富野康日己：急速進行性糸球体腎炎．Nephrology Frontier．メディカルレビュー社、東京、vol.1: 50-53, 2001 3. 鈴木　仁、富野康日己：IgA腎症の診療指針. 臨床と研究．大石了三編、大道学館出版部、福岡、第79巻: 29-30, 2002 4. 鈴木　仁：インドメタシン-非ステロイド性抗炎症薬．腎機能低下患者への薬の使い方, 富野康日己編, 医学書院東京, 224-225, 2005 5. 鈴木　仁、富野康日己：IgA腎症の診療指針. 腎臓．日本腎臓財団東京医学社東京、vol.26: 5-10, 2003 6. 鈴木　仁、川村哲也、富野康日己：IgA腎症治療ガイドライン. 最新医学新しい診断と治療のABC　IgA腎症．最新医学社大阪: 180-186, 2004 7. 鈴木　仁、富野康日己：IgA腎症診療指針．腎臓ナビゲーター, メディカルレビュー社東京：198-199, 2004 8. 鈴木　仁：緑膿菌感染症．感染の理解と消毒・滅菌の看護へのいかしかた第2版, 富野康日己編, 医歯薬出版東京, 103-108, 2005 9. 鈴木　仁、富野康日己：IgA腎症の診療指針, 腎と透析．東京医学社東京, 212-216, 2005 10. 鈴木　仁、富野康日己：IgA腎症：成人予後からみた臨床・病理学的分類と治療原則．腎疾患・透析最新の治療．飯野靖彦槇野博史編、南江堂、東京、92-96, 2005 11. 鈴木　祐介、相澤　昌史、鈴木　仁、富野　康日己：腎・電解質：IgA腎症の発症と遺伝因子 –動物モデル解析の有用性- 臨床遺伝学’ 06．田中正広編、最新医学社大阪, 195-202, 2006 12. 鈴木　仁、富野康日己：IgA腎症 -動物モデルでの検討-. エキスパートのための腎臓内科学, 富野康日己編, 中外医学社東京, 163-165, 2009 13. 鈴木　仁、鈴木　祐介、富野康日己：異常糖鎖を有するIgAによるシグナル伝達とIgA腎症．腎と透析．東京医学社東京, 第67巻, 323-327, 2009 14. 鈴木　仁、富野　康日己：IgA腎症における糖鎖異常IgA1と免疫複合体の病的意義．医学のあゆみ, 医歯薬出版東京, 第232巻, 1107-1112, 2010 15. 鈴木　仁、鈴木　祐介、富野　康日己：IgA腎症における糖鎖異常．糸球体疾患－腎炎からネフローゼまで、最高の診療を目指して．内科, 南江堂東京, 106巻: 98-101, 2010 16. 富野康日己、鈴木　祐介、鈴木　仁：IgA腎症の疾患感受性遺伝子解析-動物モデルからヒトへ-．臨床遺伝学’10, 最新医学社大阪, 65巻: 205-213, 2010 17. 鈴木　仁：腎機能低下患者への薬の使い方「コルヒチン、インドメタシン」．富野康日己編, 医学書院東京, 198-199, 210-211, 2010 18. 鈴木　仁、富野康日己：糖鎖異常IgA1．IgA腎症診療マニュアル, 富野康日己編, 南江堂東京, 11-17, 2011 19. 鈴木　仁、富野康日己：「IgA腎症の成因」．Annual Review 腎臓, 富野康日己成田一衛柏原直樹編, 中外医学社東京, 21-29, 2011 20. 鈴木　仁：「我が国では、IgA腎症が大変多いと聞きましたがどうしてですか？項目42-44」生活習慣病・腎臓病・高血圧対策Q&A100－みなさんのご質問にお答えします．富野康日己編, 中外医学社東京, p ~ , 2011 21. 鈴木　仁：「Fe, TIBC, UIBC, トランスフェリン、Mg」．臨床検査express, 富野康日己編, 中外医学社, 東京, 114-116, 2011 22. 鈴木　仁：「IgA腎症の発症、扁桃病巣感染、粘膜免疫」．IgA腎症診療ガイドQ&A　進行性腎障害診療指針シリーズ, 診断と治療社東京, 34-35, 2011 23. 鈴木　仁、富野康日己：「IgA腎症の病態における扁桃B細胞の役割および尿中糖鎖異常IgA1測定の有用性」．Annual Review 腎臓, 富野康日己成田一衛柏原直樹編, 中外医学社東京, p100~107 , 2012 24. 鈴木　仁、富野康日己：「IgA分子の糖鎖異常と発症・進展における役割」．腎と透析72巻1号, 東京医学社, 東京, p 25~30 , 2012 25. 鈴木　仁、富野康日己：「Case IgA腎症」．腎臓専門医のためのケースメソッドアプローチ　　, 2012 26. 鈴木　仁：「無酢酸透析液と従来の重曹透析液ではどう違うのですか？また、高ナトリウム透析とは何ですか？」．ナーシングケアQ&A 第2版、富野康日己編、総合医学社、2012 27. 鈴木　仁、鈴木祐介、富野康日己：IgA腎症患者扁桃とTLR．Annual Review 腎臓: 47-56, 2013 28. 鈴木　仁：「蛋白尿を抑える降圧薬」「CHDFの適応」．CKD診療テキスト．富野康日己編、中外医学社、2013 29. 鈴木　仁：「siRNAとshRNA」．分子腎臓学実験操作法．富野康日己編、中外医学社、2013 30. 鈴木　仁：「毒薬、麻薬、向精神薬の管理」．根拠がわかる看護実践禁忌ナビ．富野康日己、照沼則子編、南江堂、2013, P24-26 31. 鈴木　仁：「アンジオテンシン変換酵素阻害薬とは」腎臓病・高血圧と薬剤実践Q&A, 2014, P163-164 32. 鈴木　仁：「慢性糸球体腎炎」P117-123, 2014, 医歯薬出版 33. 鈴木　仁：「直接的レニン阻害薬とは」腎臓病・高血圧と薬剤実践Q&A, 2013, P165-166 34. 鈴木　仁：「良性腎硬化症、悪性腎硬化症」Newエッセンシャル腎臓内科学 P259-263, 2015, 富野康日己編、医歯薬出版 35. 鈴木　仁、鈴木祐介：「IgA腎症早期発見のための新規バイオマーカーを用いた血尿の2次スクリーニングの試み」．腎・高血圧の最新治療,第4巻1号, 28-33, 2015 36. 鈴木　仁：IgA腎症の病態における糖鎖異常IgA1の意義とバイオマーカーの有用性．医学のあゆみ、Vol. 255, 1095-1099, 2015 37. 鈴木祐介、鈴木　仁、富野康日己：病因に基づくバイオマーカーを用いたIgA腎症の早期発見・診断・治療の試み．Annual Review 腎臓 2015, 中外医学社 p87-93 38. 鈴木祐介、鈴木　仁、武藤正浩：IgA腎症の根治治療を目指した病因関連バイオマーカーの臨床応用と基礎的背景．Annual Review 腎臓 2016, 中外医学社 p87-93 39. 鈴木　仁、鈴木祐介：IgA腎症における検尿の意味と新規バイオマーカー．Nephrology Frontier 15: 16-19、2016 40. 鈴木　仁、わが国におけるIgA腎症分類と各ステージの代表的治療法は？, これだけは知っておきたい透析療法　富野康日己（編）, 中外医学社,2016, 10-13 41. 鈴木　仁：IgA腎症研究の最前線～基礎から臨床応用へ～．Bio Clinica 32: 34-39, 2017 42. 鈴木　仁、鈴木祐介：バイオマーカーを用いた診断、活動性予測．腎と透析 82: 595-599, 2017 43. 鈴木　仁：成人IgA腎症の尿所見の特徴と診かた2018, P234-238, 中外医学社, 2018 44. 楢原美希、鈴木　仁：プレドニゾロン．歯科医の薬の使い方 2018, P174-176, デジタルダイヤモンド社 45. 鈴木　仁：CKDのアウトリーチ活動の重要性　現在の健診における腎スクリーニング検査は有用ですか？．腎臓専門医のためのCKD診療2018, P29-31 46. 鈴木　仁：IgA腎症の家族歴は腎症の発症や進行に関連するか。IgAにおいて血尿は腎機能予後に影響するか。P111-113, 2018、東京医学社 47. 鈴木　仁：IgA腎症の基礎知識　IgA腎症の進展機序をマーカーから考える．IgA腎症の臨床湯村和子編、2018年9月号、東京医学社, P11-17 48. 禾千絵子、鈴木　仁、鈴木祐介：IgA腎症の基礎知識　IgA腎症の発症機序から考える治療の妥当性．IgA腎症の臨床　湯村和子編、2018年9月号, 東京医学社, P2-7 49. 鈴木　仁、鈴木祐介：IgA腎症の新規分子標的治療薬の可能性．P187-190, IgA腎症の臨床　湯村和子編、2018年9月号, 東京医学社 50. 鈴木　仁、鈴木祐介：Tonsil induced autoimmune/inflammatory syndrome (TIAS) としてのIgA腎症．アレルギー・免疫、2018年6月号、25, P802-809, 医薬ジャーナル社 51. 鈴木　仁：IgA腎症-新規バイオマーカーを用いた早期診断と活動性評価．腎と透析86巻5号、2019年、東京医学社 52. 鈴木　仁、鈴木祐介：IgA腎症：発症要因と診断法、早期治療への展開．腎疾患・透析最新の治療2020-2022、2019年, 南江堂 53. 鈴木　仁、鈴木祐介：IgA腎症のエンドポイント．医学のあゆみ269巻7号、2019年、医歯薬出版 54. 鈴木　仁：バイオマーカー、免疫複合体の特徴と成因．IgA腎症の病態と治療．P93-96, 2019年、中外医学社

研究テーマ

腎臓内科

研究業績（論文）

英文原著
1. Suzuki H, Kurusu A, Hishiki T, Funabiki K, Shirato I, Tomino Y: A cese of IgA nephropathy with a long history (32 years) in relatively poor prognosis group. Hong Kong J Nephrol 5: 44-49, 2003
2. Tomino Y, Suzuki H, Horikoshi S, Imai E, Miyazaki M, Ohzono Y, Harada T, Yoshida H, Kawamura T, Kobayashi Y, Suzuki S, Nitta K, Hotta O, Yoshikawa N, Endoh M and Sakai H: Multicenter trial of adrenocorticosteroids in Japanese patients with IgA nephropathy-results of the special study group (IgA nephropathy) on progressive glomerular disease, Ministry of Health, Labor and Walfare of Japan. Current Topics in Steroid Research 4: 93-98, 2004
3. Suzuki H, Suzuki Y, Yamanaka T, Hirose S, Toei J, NIshimura H, Horikoshi S, Tomino Y: Genome-wide scan in novel IgA nephropathy model identifies susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23. J Am Soc Nephrol 16: 1289-99, 2005
4. Moore JS, Kulhavy R, Tomana M, Moldoveanu Z, Suzuki H, Brown R, Hall S, Kilian M, Poulsen K, Mestecky J, Julian BA, Novak J: Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol 44: 2598-2604, 2007
5. Raska M, Moldoveanu Z, Suzuki H, Brown R, Kulhavy R, Andrasi J, Hall S, Vu HL, Carlsson F, Lindahl G, Tomana M, Julian BA, Wyatt RJ, Mestecky J, Novak J: Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells. J Mol Biol 369: 69-78, 2007
6. Suzuki H, Suzuki Y, Aizawa M, Yamanaka T, Kihara M, Pang H, Horikoshi S, Tomino Y: Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int 72: 319-327, 2007
7. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcón GS, Kimberly RP, Tomino Y, Mestecky J, Novak J: IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly-glycosylated IgA1. J Clin Invest 118: 629-639, 2008
8. Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, Renfrow MB, Novak L, Wyatt RJ, Novak J: Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 31: 29-37, 2008
9. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, Kanou T, Tsukaguchi H, Novak J, Horikoshi S, Tomino Y: Toll-Like Receptor 9 Affects Severity of IgA Nephropathy. J Am Soc Nephrol 19: 2384-2395, 2008
10. Julian BA, Suzuki H, Spasovski G, Suzuki Y, Tomino Y, Novak J: Application of proteomic analysis to renal disease in the clinic. Proteomics Clin Appl 3: 1023-1028, 2009
11. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668-1677, 2009
12. Mischak H, Kolch W, Aivaliotis M, Bouyssié D, Court M, Dihazi H, Dihazi GH, Franke J, Garin J, Anne Gonzalez de Peredo5,6, Iphöfer A, Jänsch L, Lacroix C, Makridakis M, Masselon C, Metzger J, Monsarrat B, Mrug M, Norling M, Novak J, Pich A, Pitt A, Bongcam-Rudloff E, Siwy J, Suzuki H, Thongboonkerd V, Wang LS, Zoidakis J, Zürbig P, Schanstra JP, Vlahou A: Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 4: 464-478, 2010
13. Hu SL, Colvin GA, Rifai A, Suzuki H, Novak J, Esparza A, Farooqi S, Julian BA: Glomerulonephritis after Hematopoietic Cell Transplantation: IgA Nephropathy with Increased Excretion of Galactose-deficient-IgA1. Nephrol Dial Transplant 25: 1708-1713, 2010
14. Gomes MM, Suzuki H, Brooks MT, Tomana M, Moldoveanu Z, Mestecky J, Julian BA, Novak J, Herr AB: Recognition of Galactose-Deficient O-Glycans in the Hinge Region of IgA1 by N-Acetylgalactosamine-Specific Snail Lectins: A Comparative Binding Study. Biochemistry 13: 5671-5682, 2010
15. Takahashi K, Wall SB, Suzuki H, Smith AD, Hall S, Paulsen K, Kilian M, Mobley JA, Julian BA, Mestecky J, Novak J, Renfrow MB: Clustered O-glycans of IgA1: Defining macro- and micro-heterogeneity by use of electron capture/transfer dissociation. Mol Cell Proteomics 9: 2545-2557, 2010
16. Lindfors K, Suzuki H, Novak J, Collin P, Saavalainen P, Koskinen L, Maki M, Kaukinen K: Galactosylation of serum IgA1 O-glycan in celiac disease. J Clin Immunol 31: 74-79, 2010
17. Kiryluk K, Moldoveanu Z, Sanders JT, Elison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ: Aberrant Glycosylation of IgA1 is Inherited in Pediatric IgA Nephropathy and Henoch-Schönlein Purpura Nephritis. Kidney Int 80: 79-87, 2011
18. Tomino Y, Shimizu Y, Hamada C, Kurusu A, Ohsawa I, Suzuki Y, Tsuge T, Io H, Kobayashi N, Takeda Y, Asanuma K, Tanaka Y, Suzuki H, Nakata J, Takara K, Horikoshi S: One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease. J Nephrol 24: 756-763, 2011
19. Kajiyama T, Suzuki Y, Kihara M, Suzuki H, Horikoshi S, Tomino Y: Different pathological roles of Toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy. Clin Devl Immunol, 2011:819646, 2011
20. Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, Tomino Y: Pathological role of tonsillar B cells in IgA nephropathy. Clin Devl Immunol, 2011:639074, 2011
21. Camilla R, Suzuki H, Daprà V, Loiacono E, Peruzzi L, Amore A, Ghiggeri GM, Mazzucco G, Scolari F, Gharavi AG, Appel GB, Troyanov S, Novak J, Julian BA, Coppo R. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 6: 1903-11, 2011
22. Novak J, Kafkova LR, Suzuki H, Tomana M, Matousovic K, Brown R, Stacy Hall, Sanders JT, Eison TM, Moldoveanu Z, Novak L, Novak Z, Mayne R, Julian BA, Mestecky J, Wyatt RJ: IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant,26: 3451-3457, 2011
23. Suzuki Y, Suzuki H, Sato D, Kajiyama T, Okazaki K, Hashimoto A, Kihara M, Yamaji K, Satake K, Nakata J, Aizawa M, Novak J, Tomino Y: Reevaluation of the mucosa-bone marrow axis in IgA nephropathy with animal models. Adv Otorhinolaryngol 72: 64-7, 2011
24. Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Mestecky J, Suzuki H: Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol 72: 60-3, 2011
25. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795-1803, 2011
26. Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, Horikoshi S, Ikeda K, Tomino Y: Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant 27: 1090-7, 2012
27. Okazaki K, Suzuki Y, Otsuji M, Suzuki H, Kihara M, Kajiyama T, Hashimoto A, Nishimura H, Brown R, Hall S, Novak J, Izui S, Hirose S, Tomino Y: Development of a Model of Early-Onset IgA Nephropathy. J Am Soc Nephrol 23: 1364-1374, 2012
28. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J: Serum autoantibodies specific for galactose-deficient IgA1 associate with disease progression in IgA nephropathy. J Am Soc Nephrol 23: 1579-1587, 2012
29. Hashimoto A, Suzuki Y, Suzuki H, Ohsawa I, Brown R, Hall S, Tanaka Y, Novak J, Ohi H, Tomino Y: Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am J Pathol 181: 1338-1347, 2012
30. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG: Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genet 8: e1002765, 2012
31. Schoeb TR, Jarmi T, Hicks MJ, Henke S, Zarjou A, Suzuki H, Kramer P, Novak J, Agarwal A, Bullard DC: Endothelial nitric oxide synthase inhibits the development of autoimmune-mediated vasculitis in mice. Arthritis Rheum 64: 4114-4124, 2012
32. Nakata J, Ohsawa I, Onda K, Tanimoto M, Kusaba G, Takeda Y, Kobayashi N, Asanuma K, Tanaka Y, Sato M, Inami Y, Suzuki H, Suzuki H, Masuda A, Nonaka K, Sasaki Y, Hisada A, Hamada C, Horikoshi S, Tomino Y. Risk of overestimation of kidney function using GFR-estimating equations in patients with low inulin clearance. J Clin Lab Anal 26: 248-53, 2012
33. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Horikoshi S, Novak J, Tomino Y: Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. Nephrol Dial Transplant 28: 320-326, 2013
34. Hastings MC, Moldoveanu Z, Suzuki H, Berthoux F, Julian BA, Sanders JT, Renfrow MB, Novak J, Wyatt RJ: Biomarkers in IgA Nephropathy: Relationship to Pathogenetic Hits. Expert Opin Med Diagn 7: 615-627, 2013
35. Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 18: 481-6, 2014. doi: 10.1007/s10157-013-0849-x.
36. Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol.18: 770-777, 2014. doi: 10.1007/s10157-013-0921-6.
37. Maiguma M, Suzuki Y, Suzuki H, Okazaki K, Aizawa M, Muto M, Tomino Y. Dietary zinc is a key environmental modifier in the progression of IgA nephropathy. PLoS One 28, e90558, 2014. doi: 10.1371/journal.pone.0090558.
38. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuzaki K, Horikoshi S, Novak J, Tomino Y. Changes in Nephritogenic Serum Galactose-Deficient IgA1 in IgA Nephropathy following Tonsillectomy and Steroid Therapy. PLoS One 21, e89707, 2014. doi: 10.1371/journal.pone.0089707.
39. Aizawa M, Suzuki Y, Suzuki H, Pang H, Kihara M, Nakata J, Yamaji K, Horikoshi S, Tomino Y. Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy. PLoS One 17: e95365, 2014. doi: 10.1371/journal.pone.0095365.
40. Yanagawa H*, Suzuki H*, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 23: e98081, 2014. doi: 10.1371/journal.pone.0098081.
41. Satake K, Shimizu Y, Sasaki Y, Yanagawa H, Suzuki H, Suzuki Y, Horikoshi S, Honda S, Shibuya K, Shibuya A, Tomino Y. Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy. BMC Nephrol. 2014 Jun 13;15:89. doi: 10.1186/1471-2369-15-89
42. Kiryluk K, Suzuki H, Gharavi A et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187-96, 2014. doi: 10.1038/ng.3118. (92, 77)
43. Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, Tomino Y, Gharavi AG, Novak J. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem 21: 5330-9, 2014. doi: 10.1074/jbc.M113.512277.
44. Suzuki Y, Suzuki H, Makita Y, Takahata A, Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H, Okazaki K, Tomino Y. Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers. Int J Nephrol Renovasc Dis 7: 409-14, 2014. doi: 10.2147/IJNRD.S50513.
45. Suzuki H, Suzuki Y, Novak J, Tomino Y. Development of Animal Models of Human IgA Nephropathy. Drug Discov Today: Dis Model, 11: 5-11, 2014. doi:10.1016/j.ddmod.2014.07.002
46. Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y. The kinetics of glomerular deposition of nephritogenic IgA. PLoS One 9: e113005, 2014. doi: 10.1371/journal.pone.0113005. IF:2.766
47. Kim YG, Alvarez M, Suzuki H, Hirose S, Izui S, Tomino Y, Huard B, Suzuki Y. Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS One 10: e0137044, 2015. doi: 10.1371/journal.pone.0137044. IF:2.766
48. Stuchlova Horynova M, Vrablikova A, Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian BA, Renfrow MB, Novak J, Raska M. N-Acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Nephrol Dial Transplant 30: 234-8, 2015. doi: 10.1093/ndt/gfu308. IF:4.47, CI:6
49. Suzuki Y, Suzuki H, Yasutake J, Tomino Y. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting. Expert Opin Biol Ther 15: 583-93, 2015. doi: 10.1517/14712598.2015.
50. Novak J, Rizk D, Takahashi K, Zhang XW, Bian Q, Ueda H, Ueda Y, Reily C, Lai LY, Hao C, Novak L, Huang ZQ, Renfrow MB, Suzuki H, Julian BA. New Insights into the Pathogenesis of IgA Nephropathy. Kidney Dis 1: 8-18, 2015. DOI:10.1159/000382134
51. Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, Kaneko E, Tomino Y. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 30: 1315-21, 2015 doi: 10.1093/ndt/gfv221. IF:4.47, CI:6
52. Diciolla M, Binetti G, Noia TD, Pesce F, Schena FP, Vagane AN, Bjorneklett R, Suzuki H, Tomino Y, Naso D: Patient Classification and Outcome Prediction in IgA Nephropathy. Computers in Biology and Medicine 66: 278-286, 2015 IF:1.836,CI:2
53. Pesce F, Diciolla M, Binetti G, Naso D, Ostuni VC, Di Noia T, Vågane AM, Bjørneklett R, Suzuki H, Tomino Y, Di Sciascio E, Schena FP. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrol Dial Transplant. 31: 80-6, 2016 doi: 10.1093/ndt/gfv232 IF:4.47, CI:2
54. Yamanaka T, Tamauchi H, Suzuki Y, Suzuki H, Horikoshi S, Terashima M, Iwabuchi K, Habu S, Okumura K, Tomino Y. Release from Th1-type immune tolerance in spleen and enhanced production of IL-5 in Peyer's patch by cholera toxin B induce the glomerular deposition of IgA. Immunobiology 221: 577-85, 2016. doi: 10.1016/j.imbio.2015.12.001 IF:2.72, CI:0
55. Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, Crowley MR, Hargett A, Zhang Z, Suzuki H, Hall S, Wyatt RJ, Julian BA, Renfrow MB, Gharavi AG, Novak J. Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy. J Am Soc Nephrol 27: 3278-3284, 2016 10.1681/ASN.2014101044 IF:8.966, CI:4
56. Matsuzaki K*, Suzuki H*, Kobayashi T, Shimizu Y, Tomino Y. Analysis of Predictive Factors for Deterioration of Renal Function in Chronic Kidney Disease Patients. J Nephrol Ther 6: 240, 2016. doi: 10.4172/2161-0959.1000240 IF:0, CI:0
57. Kato TS, Nakamura H, Murata M, Kuroda K, Suzuki H, Yokoyama Y, Shimada A, Matsushita S, Yamamoto T, Amano A. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery. BMC Cardiovasc Disord 13 : 181-189, 2016 doi: 10.1186/s12872-016-0341-0 IF:1.832, CI:0
58. Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z, Wyatt RJ, Novak J, Julian BA. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? Dis Markers 2016. doi: 10.1155/2016/7806438. IF:2.348,CI:1
59. Maruyama S, Gohda T, Suzuki Y, Suzuki H, Sonoda Y, Ichikawa S, Li Z, Murakoshi M, Horikoshi S, Tomino Y. Beneficial effects of tonsillectomy plus steroid pulse therapy on inflammatory and tubular markers in patients with IgA nephropathy. Kidney Res Clin Pract 35: 233-236, 2016 doi: 10.1016/j.krcp.2016.09.002 IF:0, CI:1
60. Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakai S, Righini C, Maiguma M, Izui S, Tomino Y, Huard B, Suzuki Y. Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy. J Am Soc Nephrol 28: 1227-1238, 2017 doi: 10.1681/ASN.2016050496 IF:8.966, CI:3
61. Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J. GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 10: e1006609, 2017 doi: 10.1371/journal.pgen.1006609
62. Berthoux F, Suzuki H, Mohey H, Maillard N, Mariat C, Novak J, Julian BA. Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation. J Am Soc Nephrol 28: 1943-1950, 2017 doi: 10.1681/ASN.2016060670
63. Suzuki H, Kihara M, Mano S, Kobayashi T, Kanaguchi Y, Hidaka T, Gohda T, Suzuki Y: Efficacy and Safety of Denosumab for the Treatment of Osteoporosis in Patients with Chronic Kidney Disease. J Clin Exp Nephrol 2: 1-5, 2017, DOI: 10.21767/2472-5056.100030
64. Murakoshi M, Gohda T, Sonoda Y, Suzuki H, Tomino Y, Horikoshi S, Suzuki Y: Effect of tonsillectomy with steroid pulse therapy on circulating tumor necrosis factor receptors 1 and 2 in IgA nephropathy. Clin Exp Nephrol 21: 1068-1074, 2017 doi: 10.1007/s10157-017-1408-7
65. Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z, Kiryluk K, Suzuki Y, Wyatt RJ, Tomino Y, Gharavi AG, Weinmann A, Julian BA, Willey CD, Novak J. Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. Kidney Int Rep 19: 1194-1207, 2017. doi: 10.1016/j.ekir.2017.07.002
66. Placzek W, Yanagawa H, Makita Y, Renfrow MB, Julian BA, Rizk DV, Suzuki Y, Novak J, Suzuki H: Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. Plos One 11: e0190967, 2018. doi: 10.1371/journal.pone.01909672018, IF:2.766
67. Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamazaki K, Sofue T, Kano T, Suzuki Y: IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1 oriented pathogenesis Kidney Int 93: 700-705, 2018, IF:8.429
68. Suzuki H, Suzuki Y: Murine model of human IgA nephropathy. Seminar in Nephrol 38: 513-520, 2018, IF:3.35
69. Suzuki H: Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol 23: 26-31, 2018. doi: 10.1007/s10157-018-1582-2, IF:2.016,
70. Honda D, Ohsawa I, Shimizu Y, Maiguma M, Hidaka T, Suzuki H, Io H, Mano S, Takahara H, Rinno H, Tomino Y, Suzuki Y: A case of suffocation by an acute airway edema in a patient with hereditary angioedema invoking the need for urgent improvements of treatment availability in Japan. Intern Med 57: 3193-3197, 2018.　 doi: 10.2169/internalmedicine.9262-17, IF:0.817
71. Gohda T, Suzuki H, Hidaka T, Ueda S, Suzuki Y: An update of pathogenesis and treatment of major chronic kidney diseases. Juntendo Medical Journal 64:227-234, 2018
72. Sofue T, Suzuki H, Ueda N, Kushida Y, Minamino T: Post-transplant immunoglobulin A deposition and nephropathy in allografts. Nephrology 23: 4-9, 2018, IF:2.178
73. Yamazaki K, Suzuki H, Yasutake J, Yamazaki Y: Galactose-deficient IgA1 specific antibody recognizes GalNAc modified unique epitope on hinge region of IgA1. Monoclon Antib Immunodiagn Immunother 37: 252-256, 2018
74. Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG: A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int 19: 30174-7, 2019
75. Suzuki H: Multi-hit pathogenesis of IgA nephropathy. Juntendo Medical Journal 65: 537-542, 2019
76. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y: TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int 97: 340-349, 2020
77. Koshida T, Wu S, Suzuki H, Wanchoo R, Bijol V, Tomita S, Suzuki Y, Jhaveri K: Thrombotic Microangiopathy in Dasatinib-treated patients with Chronic Myeloid Leukemia. Journal of Onco-Nephrology, 2019 in press.
78. Suzuki H, Moldoveanu Z, Julian BA, Wyatt RJ, Novak J: Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int Rep 30: 1717-1724, 2019
79. Murayama G, Chiba A, Suzuki H, Nomura A, Mizuno T, Kuga T, Nakamura S, Amano H, Hirose S, Yamaji K, Suzuki Y, Tamura N, Miyake S: Critical role for mucosal-associated invariant T cells as regulators and therapeutic targets in systemic lupus erythematosus. Frontiers in Immunology 29: 10: 2681, 2019
80. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y: TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int 97: 340-349, 2020
81. Yamada K, Huang Z, Raska M, Reily C, Anderson J, Suzuki H, Kiryluk K, Gharavi AG, Julian BA, Willey CD, Novak J: Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy. Kidney Dis (Basel), 6: 168-180, 2020
82. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, Cui Z, Lin L, Hu X, Yu X, Xu J, Liu G, Caliskan Y, Sidore C, Balderes O, Rosen RJ, Bodria M, Zanoni F, Zhang JY, Krithivasan P, Mehl K, Marasa M, Khan A, Ozay F, Canetta PA, Bomback AS, Appel GB, Sanna-Cherchi S, Sampson MG, Mariani LH, Perkowska-Ptasinska A, Durlik M, Mucha K, Moszczuk B, Foroncewicz B, Pączek L, Habura I, Ars E, Ballarin J, Mani LY, Vogt B, Ozturk S, Yildiz A, Seyahi N, Arikan H, Koc M, Basturk T, Karahan G, Akgul SU, Sever MS, Zhang D, Santoro D, Bonomini M, Londrino F, Gesualdo L, Reiterova J, Tesar V, Izzi C, Savoldi S, Spotti D, Marcantoni C, Messa P, Galliani M, Roccatello D, Granata S, Zaza G, Lugani F, Ghiggeri G, Pisani I, Allegri L, Sprangers B, Park JH, Cho B, Kim YS, Kim DK, Suzuki H, Amoroso A, Cattran DC, Fervenza FC, Pani A, Hamilton P, Harris S, Gupta S, Cheshire C, Dufek S, Issler N, Pepper RJ, Connolly J, Powis S, Bockenhauer D, Stanescu HC, Ashman N, Loos RJF, Kenny EE, Wuttke M, Eckardt KU, Köttgen A, Hofstra JM, Coenen MJH, Kiemeney LA, Akilesh S, Kretzler M, Beck LH, Stengel B, Debiec H, Ronco P, Wetzels JFM, Zoledziewska M, Cucca F, Ionita-Laza I, Lee H, Hoxha E, Stahl RAK, Brenchley P, Scolari F, Zhao MH, Gharavi AG, Kleta R, Chen N, Kiryluk K: The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications 11: 1600, 2020.
83. Shirai Y, Miura K, Yabuuchi T, Nagasawa T, Ishizuka K, Takahashi K, Taneda S, Honda K, Yamaguchi Y, Suzuki H, Suzuki Y, Hattori M: Rapid progression to end-stage renal disease in a child with IgA-dominant infection-related glomerulonephritis associated with parvovirus B19. CEN Case Reports 9:423-430, 2020
84. Kubo A, Hidaka T, Nakayama M, Sasaki Y, Takagi M, Suzuki H, Suzuki Y: Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases. BMC Nephrol 18: 402, 2020
85. Takahata A, Arai S, Hiramoto E, Kitada K, Kato R, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y: Crucial Role of AIM/CD5L in the Development of Glomerular Inflammation in IgA Nephropathy. J Am Soc Nephrol 31: 2013-2024, 2020
86. Wada T, Hara A, Muso E, Maruyama S, Kato S, Furuichi K, Yoshimura K, Toyama T, Sakai N, Suzuki H, Tsukamoto T, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Goto S, Sakamaki Y, Yokoyama H, Mori N, Tanaka S, Yuzawa Y, Hasegawa M, Matsubara T, Wada J, Tanabe K, Masutani K, Abe Y, Tsuruya K, Fujimoto S, Iwatsubo S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Sofue T, Miyata H, Nakano T, Ohtake T, Kobayashi S; LICENSE study Group.: Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia. Clin Exp Nephrol 25: 1-8, 2021
87. Han W, Suzuki S, Watanabe S, Nakata M, Ichikawa D, Koike J, Oda T, Suzuki H, Suzuki Y, Shibagaki Y: Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis: A case report. Medicine 100: e24460, 2021
88. Lee M, Suzuki H, Kato R, Fukao Y, Nakayama M, Kano T, Makita Y, Suzuki Y: Renal pathological analysis using galactose deficient IgA1-specific monoclonal antibody is a strong tool for differentiation primary IgA nephropathy from secondary IgA nephropathy. CEN Case Reports 10: 17-22, 2021
89. Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N, Huang ZQ, Knoppova B, Khan A, Hall S, Yanagawa H, Brown R, Winstead CJ, O’Quinn DB, Weinmann A, Gharavi AG, Kiryluk K, Julian BA, Weaver CT, Suzuki Y, Novak J: Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J Autoimmune 118: 102593, 2021　
89. Kano T, Suzuki H*, Makita Y, Fukao Y, Suzuki Y: Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. Kidney Int 100: 364-376, 2021 doi: 10.1016/j.kint.2021.04.026. IF: 8.945, CI:N/D
90. Matsuzaki K, Suzuki H, Kawamura T, Tomino Y, Suzuki Y: Utility of remission criteria for the renal prognosis of IgA nephropathy. Clin Exp Nephrol 25: 988-995, 2021. doi: 10.1007/s10157-021-02069-w. IF:1.854, CI:N/D
91. Suzuki Y, Monteiro R, Coppo R, Suzuki H: The phenotypic difference of IgA nephropathy and its race/gender-dependent molecular mechanisms. Kidney 360 2:1339-1348, 2021
92. Akira M, Suzuki H*, Ikeda A, Iwasaki M, Honda D, Takahara H, Rinno H, Tomita S, Suzuki Y: Atypical histological abnormalities in an adult patient with nephronophthisis harboring NPHP1 deletion: a case report. BMC Nephrol 22: 261, 2021 doi: 10.1186/s12882-021-02466-z
93. Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I, Sugiyama H, Fujimoto S, Miura K, Matsumura C, Goto Y, Suzuki H, Kuroki A, Yoshino A, Nakatani S, Hiromura K, Yamamoto R, Yokoyama H, Narita I, Isaka Y: Demographic, Clinical Characteristics and Treatment Outcomes of Immune-Complex Membranoproliferative Glomerulonephritis and C3 Glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. Plos One 16: e0257397, 2021. doi: 10.1371/journal.pone.0257397
94. Suzuki H, Kikuchi M, Koike K, Komatsu H, Matsuzaki K, Takahashi K, Ichikawa D, Okabe M, Obata Y, Katafuchi R, Kihara M, Kohatsu K, Sasaki T, Shimizu A, Nakanishi K, Fukuda A, Miyazaki Y, Muto M, Yanagawa H, Suzuki Y, Fujimoto S, Furuichi K, Okada H, Narita I: A digest from evidence based clinical practice guideline for IgA nephropathy 2020. Clin Exp Nephrol, 25: 1269-1276, 2021. IF:1.77　 10.1007/s10157-021-02095-8.
95. Suzuki H*, Novak J: IgA glycosylation and immune complex formation in IgA nephropathy. Semin Immunopathol, 43: 669-678, 2021 IF:7.48, CI:N/D, 10.1007/s00281-021-00883-8
96. Murakami Y, Fukui R, Tanaka R, Motoi Y, Kanno A, Sato R, Yamaguchi K, Amano H, Furukawa Y, Suzuki H, Suzuki Y, Tamura N, Yamashita N, Miyake K: Anti-TLR7 antibody protects against lupus nephritis in NZBWF1 mice by targeting B cells and patrolling monocytes. Frontiers in Immunology, 12:777197, 2021. IF:5.085
97. Hara A, Wada T, Eri Muso, Maruyama S, Kato S, Furuichi K, Yoshimura K, Toyama T, Sakai N, Suzuki H, Tsukamoto T, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Goto S, Sakamaki Y, Yokoyama H, Mori N, Tanaka S, Yuzawa Y, Hasegawa M, Matsubara T, Wada J, Tanabe K, Masutani K, Abe Y, Tsuruya K, Fujimoto S, Iwatsubo S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Sofue T, Miyata H, Nakano T, Ohtake T, Kobayashi S: Long-term effects of low-density lipoprotein apheresis on diabetic patients with severe proteinuria and hypercholesterolemia: A multicenter prospective study. Renal Replacement Therapy, in press
98. Matsuzaki K, Aoki R, Nihei Y, Suzuki H, Kihara M, Yokoo T, Kashihara N, Narita I and Suzuki Y. Gross Hematuria after SARS-CoV-2 Vaccination: Questionnaire Survey in Japan. Clin Exp Nephrol,29: 1-2, 2021. IF:1.77
99. Ishida M, Matsuzaki K, Ikai H, Suzuki H, Kawamura T, Suzuki Y: Cost analysis of screening for IgA nephropathy using novel biomarkers. Value Health Reg Issues, 29:8-15, 2022
100. Nihei Y, Kishi M, Suzuki H, Koizumi A, Yoshida M, Hamaguchi S, Iwasaki M, Fukuda H, Takahara H, Kihara M, Tomita S, Suzuki Y. IgA nephropathy with gross hematuria following a COVID-19 mRNA vaccination. Intern Med 61:1033-1037, 2022
101. Fukao Y, Suzuki H*, Kim JS, Jeong KW, Makita Y, Kano T, Nihei Y, Nakayama M, Lee M, Kato R, Chang JM, Lee SH, Suzuki Y: Galactose-deficient IgA1 as a candidate urinary marker of IgA nephropathy. J Clin Med 11: 3173, 2022
102. Makita Y, Suzuki H*, Nakano D, Yanagawa H, Kano T, Novak J, Nishiyama A, Suzuki Y: Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries. Nephrol Dial Transplant 37: 1629-1636, 2022
103. Suzuki H*, Novak J: New insight into the pathogenesis and therapies of IgA nephropathy. J Clin Med 11: 4378, 2022
104. Matsuzaki K, Ohigashi T, Sozu T, Ishida M, Kobayashi D, Suzuki H, Suzuki Y, Kawamura T: Identification of high-risk groups in urinalysis: Lessons from the longitudinal analysis of annual check-ups. Healthcare 10: 1704, 2022
105. Ishida M, Matsuzaki K *, Suzuki H, Suzuki Y, Kawamura T, Marunaka Y, Iwami T: Association between 3-Year Repetitive Isolated Hematuria and eGFR deterioration in an Apparently Healthy Population: A Retrospective Cohort Study. Int J Environ Res Public Health 19: 11466, 2022
106. Hara A, Wada T, Muso E, Maruyama S, Kato S, Furuichi K, Yoshimura K, Toyama T, Sakai N, Suzuki H, Tsukamoto T, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Goto S, Sakamaki Y, Yokoyama H, Mori N, Tanaka S, Yuzawa Y, Hasegawa M, Matsubara T, Wada J, Tanabe K, Masutani K, Abe Y, Tsuruya K, Fujimoto S, Iwatsubo S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Sofue T, Miyata H, Nakano T, Ohtake T, Kobayashi S; LICENSE study group: Effect of low-density lipoprotein apheresis on quality of life in patients with diabetes, proteinuria, and hypercholesterolemia. Blood Purif 15: 1-9, 2022
107. Yokote S, Ueda H, Shimizu A, Okabe M, Haruhara K, Sasaki T, Aoki R, Joh K, Saeki H, Tomita S, Tsuboi N, Suzuki H, Suzuki Y, Yokoo T: First diagnosis of IgA Nephropathy following SARS-CoV-2 mRNA Vaccination in Japan. Kidney Int Rep 19: 179-182, 2023
108. Yoshida M, Suzuki H*, Hamaguchi S, Iwasaki M, Fukuda H, Takahara H, Tomita S, Suzuki Y: March hemoglobinuria progressed to acute kidney injury after kendo practice: A case report. BMC Nephrol 23: 368, 2022
109. Nakayama M, Suzuki H*, Fukao Y, Lee M, Kano T, Suzuki Y: Clinical significant of intensity of glomerular galactose-deficient IgA1 deposition in IgA nephropathy. Kidney Int Rep 29: 2726-2729, 2022
110. Kiryluk K, Suzuki H, et al. Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nat Communications 13: 6859, 2022
111. Kano T, Suzuki H*, Makita Y, Nihei Y, Fukao Y, Nakayama M, Lee M, Kato R, Aoki R, Yamada K, Muto M, Suzuki Y: Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy. Biomedicines 10: 3027, 2022
112. Iwasaki M, Suzuki H*, Umezawa Y, Koshida T, Saito M, Fukuda H, MD, Takahara H, Matsuzaki K, Suzuki Y: Efficacy and safety of pemafibrate in patients with chronic kidney disease: a retrospective study. Medicine 102: e32818, 2023
113. Sofue T, Oguchi H, Yazawa M, Tsujita M, Futamura K, Nishihira M, Toyoda M, Kano T, Suzuki H: Serological and Histopathological Assessment of Galactose-Deficient Immunoglobulin A1 Deposition in Kidney Allografts: A Multicenter Prospective Observational Study. Plos One 18: e0281945, 2023
114. Misaki T, Naka S, Suzuki H, Lee M, Aoki R, Nagasawa Y, Matsuoka D, Ito S, Nomura R, Matsumoto-Nakano M, Suzuki Y, Nakano K: cnm -positive Streptococcus mutans is associated with galactose-deficient IgA in patients with IgA nephropathy. Plos One 18: e0282367, 2023
115. Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, Nakayama M, Suzuki H, Kikkawa M, Kazuno S, Miura Y, Suzuki Y, Kitamura D: Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv 9: eadd6734, 2023
116. Nihei Y, Suzuki H*, Suzuki Y. Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy. Front Immunol 11 14: 1165394, 2023
117. Elena Sanchez-Rodriguez E, Suzuki H, Kiryluk K, et al. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet 2023 in press
118. Lee M, Suzuki H*, Nihei Y, Matsuzaki K, Suzuki Y. Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management, and prognosis. CKJ 2023 in press
119. Lee M, Suzuki H*, Ogiwara K, Aoki R, Kato R, Nakayama M, Fukao Y, Nihei Y, Kano T, Makita Y, Muto M, Yamada K, Suzuki Y: Nucleotide-sensing TLR9/TLR7 system is a potential therapeutic target for IgA nephropathy. Kidney Int 2023 in press
120. Matsuzaki K, Suzuki H*, Kikuchi M, Koike K, Komatsu H, Takahashi K, Narita I, Okada H: Current treatment status of IgA nephropathy in Japan: a questionnaire survey. Clin Exp Nephrol 2023 in press

和文原著
1. 加納達也、鈴木祐介、鈴木　仁、柘植俊直、堀越哲、富野康日己：Expression of Toll-like receptor in tonsils, and therapeutic outcome of tonsillectomy and steroid pulse therapy in patients with IgA nephropathy. 順天堂医学53: 97-105, 2007
2. 鈴木祐介、鈴木　仁、富野康日己：IgA腎症の発症機序 -動物モデルの解析から-. 日本腎臓学会誌50: 456-460, 2008
3. 富野康日己、浅沼克彦、井尾浩章、鈴木仁、田中裕一、中田純一郎、小林則善、武田之彦、稲見裕子、清水芳男、柘植俊直、鈴木祐介、大澤勲、来栖厚、濱田千江子、堀越哲、若林道郎、青木竜弥、金口泰彦、彰一祐：高カリウム血症を伴う慢性腎臓病（CKD）患者に対するプリスチレンスルホン酸カルシウムゼリーの長期投与効果の検討．Therapeutic Research 31: 1471-1480, 2010
4. 高良勝彦、鈴木　仁、鈴木祐介、堀越哲、富野康日己：慢性腎臓病を伴う高血圧患者に対する塩酸ベニジピンの尿蛋白改善効果作用並びに抗酸化作用 –未治療高血圧患者における層別解析研究-．順天堂医学 57: 610-616,2011
5. 中田純一郎、濱田千江子、中野貴則、佐藤大介、鈴木祐介、鈴木　仁、井尾浩章、堀越　哲、富野康日己：好酸球性腹膜炎を契機に被嚢性腹膜硬化症（EPS）を発症した長期腹膜透析患者の1例．透析会誌44: 1031-1037, 2011
6. 山初あや、濱田千江子、野中香苗、佐々木洋平、渡邉智成、石井杏理沙、牧田侑子、仲本宙高、鈴木　仁、高原久嗣、井尾浩章、金子佳代、堀越哲、室谷典義、富野康日己：回腸末端部の石灰化が進行し、腹膜透析離脱5年後に被嚢性腹膜硬化症を発症した1症例．透析会誌45: 367-373, 2012
7. 久田温子、鈴木　仁、村越真紀、波多野琢、大澤勲、堀越哲、富野康日己：急性腎障害により意識障害を呈する高マグネシウム血症を発症した一例．日本内科学会誌 101: 3513-3515, 2012
8. 松尾清一、川村哲也、鈴木祐介、城謙輔、富野康日己、堀越哲、西野友哉、吉川徳茂、服部元史、木村健二郎、安田隆、白井小百合、柴田孝則、吉村光弘、宇都宮保典、遠藤正之、坂本なほ子、松島雅人、宮崎陽一、安田宜成、横尾隆、香美祥二、幡谷浩史、鈴木　仁、松崎慶一、内田俊也、伊藤孝史、清水章、片渕律子、久野敏、橋口明典：IgA腎症の寛解基準の提唱．日本腎臓学会誌55巻7号, 1249-1254, 2013
9. 狩野俊樹、鈴木　仁、鈴木祐介：腸管粘膜免疫異常と腸腎連関．日本腎臓学会誌59, 2017, P552-556
10. 鈴木　仁、木原正夫、鈴木祐介：IgA腎症とIgA血管炎の共通病態．東京内科医会会誌 33: 169-170, 2017
11. 鈴木　仁、鈴木祐介：腎臓病学この1年の進歩　IgA腎症の病態．日本腎臓学会誌62: 26-33, 2020
12. 1鈴木祐介、鈴木　仁：IgA腎症の病因解明と治療の進歩．日本内科学会雑誌9: 2021
13. 鈴木　仁、鈴木祐介：IgA腎症の免疫異常．日本腎臓学会誌63:250-256, 2021

和文著書
1. 鈴木　仁、白土　公：紫斑病性腎炎．EBMに基づく臨床データブック, 中外医学社東京, vol.27: 528-529, 2001
2. 鈴木　仁、山下倫史、高原久嗣、富野康日己：急速進行性糸球体腎炎．Nephrology Frontier．メディカルレビュー社、東京、vol.1: 50-53, 2001
3. 鈴木　仁、富野康日己：IgA腎症の診療指針. 臨床と研究．大石了三編、大道学館出版部、福岡、第79巻: 29-30, 2002
4. 鈴木　仁：インドメタシン-非ステロイド性抗炎症薬．腎機能低下患者への薬の使い方, 富野康日己編, 医学書院東京, 224-225, 2005
5. 鈴木　仁、富野康日己：IgA腎症の診療指針. 腎臓．日本腎臓財団東京医学社東京、vol.26: 5-10, 2003
6. 鈴木　仁、川村哲也、富野康日己：IgA腎症治療ガイドライン. 最新医学新しい診断と治療のABC　IgA腎症．最新医学社大阪: 180-186, 2004
7. 鈴木　仁、富野康日己：IgA腎症診療指針．腎臓ナビゲーター, メディカルレビュー社東京：198-199, 2004
8. 鈴木　仁：緑膿菌感染症．感染の理解と消毒・滅菌の看護へのいかしかた第2版, 富野康日己編, 医歯薬出版東京, 103-108, 2005
9. 鈴木　仁、富野康日己：IgA腎症の診療指針, 腎と透析．東京医学社東京, 212-216, 2005
10. 鈴木　仁、富野康日己：IgA腎症：成人予後からみた臨床・病理学的分類と治療原則．腎疾患・透析最新の治療．飯野靖彦槇野博史編、南江堂、東京、92-96, 2005
11. 鈴木　祐介、相澤　昌史、鈴木　仁、富野　康日己：腎・電解質：IgA腎症の発症と遺伝因子 –動物モデル解析の有用性- 臨床遺伝学’ 06．田中正広編、最新医学社大阪, 195-202, 2006
12. 鈴木　仁、富野康日己：IgA腎症 -動物モデルでの検討-. エキスパートのための腎臓内科学, 富野康日己編, 中外医学社東京, 163-165, 2009
13. 鈴木　仁、鈴木　祐介、富野康日己：異常糖鎖を有するIgAによるシグナル伝達とIgA腎症．腎と透析．東京医学社東京, 第67巻, 323-327, 2009
14. 鈴木　仁、富野　康日己：IgA腎症における糖鎖異常IgA1と免疫複合体の病的意義．医学のあゆみ, 医歯薬出版東京, 第232巻, 1107-1112, 2010
15. 鈴木　仁、鈴木　祐介、富野　康日己：IgA腎症における糖鎖異常．糸球体疾患－腎炎からネフローゼまで、最高の診療を目指して．内科, 南江堂東京, 106巻: 98-101, 2010
16. 富野康日己、鈴木　祐介、鈴木　仁：IgA腎症の疾患感受性遺伝子解析-動物モデルからヒトへ-．臨床遺伝学’10, 最新医学社大阪, 65巻: 205-213, 2010
17. 鈴木　仁：腎機能低下患者への薬の使い方「コルヒチン、インドメタシン」．富野康日己編, 医学書院東京, 198-199, 210-211, 2010
18. 鈴木　仁、富野康日己：糖鎖異常IgA1．IgA腎症診療マニュアル, 富野康日己編, 南江堂東京, 11-17, 2011
19. 鈴木　仁、富野康日己：「IgA腎症の成因」．Annual Review 腎臓, 富野康日己成田一衛柏原直樹編, 中外医学社東京, 21-29, 2011
20. 鈴木　仁：「我が国では、IgA腎症が大変多いと聞きましたがどうしてですか？項目42-44」生活習慣病・腎臓病・高血圧対策Q&A100－みなさんのご質問にお答えします．富野康日己編, 中外医学社東京, p ~ , 2011
21. 鈴木　仁：「Fe, TIBC, UIBC, トランスフェリン、Mg」．臨床検査express, 富野康日己編, 中外医学社, 東京, 114-116, 2011
22. 鈴木　仁：「IgA腎症の発症、扁桃病巣感染、粘膜免疫」．IgA腎症診療ガイドQ&A　進行性腎障害診療指針シリーズ, 診断と治療社東京, 34-35, 2011
23. 鈴木　仁、富野康日己：「IgA腎症の病態における扁桃B細胞の役割および尿中糖鎖異常IgA1測定の有用性」．Annual Review 腎臓, 富野康日己成田一衛柏原直樹編, 中外医学社東京, p100~107 , 2012
24. 鈴木　仁、富野康日己：「IgA分子の糖鎖異常と発症・進展における役割」．腎と透析72巻1号, 東京医学社, 東京, p 25~30 , 2012
25. 鈴木　仁、富野康日己：「Case IgA腎症」．腎臓専門医のためのケースメソッドアプローチ　　, 2012
26. 鈴木　仁：「無酢酸透析液と従来の重曹透析液ではどう違うのですか？また、高ナトリウム透析とは何ですか？」．ナーシングケアQ&A 第2版、富野康日己編、総合医学社、2012
27. 鈴木　仁、鈴木祐介、富野康日己：IgA腎症患者扁桃とTLR．Annual Review 腎臓: 47-56, 2013
28. 鈴木　仁：「蛋白尿を抑える降圧薬」「CHDFの適応」．CKD診療テキスト．富野康日己編、中外医学社、2013
29. 鈴木　仁：「siRNAとshRNA」．分子腎臓学実験操作法．富野康日己編、中外医学社、2013
30. 鈴木　仁：「毒薬、麻薬、向精神薬の管理」．根拠がわかる看護実践禁忌ナビ．富野康日己、照沼則子編、南江堂、2013, P24-26
31. 鈴木　仁：「アンジオテンシン変換酵素阻害薬とは」腎臓病・高血圧と薬剤実践Q&A, 2014, P163-164
32. 鈴木　仁：「慢性糸球体腎炎」P117-123, 2014, 医歯薬出版
33. 鈴木　仁：「直接的レニン阻害薬とは」腎臓病・高血圧と薬剤実践Q&A, 2013, P165-166
34. 鈴木　仁：「良性腎硬化症、悪性腎硬化症」Newエッセンシャル腎臓内科学 P259-263, 2015, 富野康日己編、医歯薬出版
35. 鈴木　仁、鈴木祐介：「IgA腎症早期発見のための新規バイオマーカーを用いた血尿の2次スクリーニングの試み」．腎・高血圧の最新治療,第4巻1号, 28-33, 2015
36. 鈴木　仁：IgA腎症の病態における糖鎖異常IgA1の意義とバイオマーカーの有用性．医学のあゆみ、Vol. 255, 1095-1099, 2015
37. 鈴木祐介、鈴木　仁、富野康日己：病因に基づくバイオマーカーを用いたIgA腎症の早期発見・診断・治療の試み．Annual Review 腎臓 2015, 中外医学社 p87-93
38. 鈴木祐介、鈴木　仁、武藤正浩：IgA腎症の根治治療を目指した病因関連バイオマーカーの臨床応用と基礎的背景．Annual Review 腎臓 2016, 中外医学社 p87-93
39. 鈴木　仁、鈴木祐介：IgA腎症における検尿の意味と新規バイオマーカー．Nephrology Frontier 15: 16-19、2016
40. 鈴木　仁、わが国におけるIgA腎症分類と各ステージの代表的治療法は？, これだけは知っておきたい透析療法　富野康日己（編）, 中外医学社,2016, 10-13
41. 鈴木　仁：IgA腎症研究の最前線～基礎から臨床応用へ～．Bio Clinica 32: 34-39, 2017
42. 鈴木　仁、鈴木祐介：バイオマーカーを用いた診断、活動性予測．腎と透析 82: 595-599, 2017
43. 鈴木　仁：成人IgA腎症の尿所見の特徴と診かた2018, P234-238, 中外医学社, 2018
44. 楢原美希、鈴木　仁：プレドニゾロン．歯科医の薬の使い方 2018, P174-176, デジタルダイヤモンド社
45. 鈴木　仁：CKDのアウトリーチ活動の重要性　現在の健診における腎スクリーニング検査は有用ですか？．腎臓専門医のためのCKD診療2018, P29-31
46. 鈴木　仁：IgA腎症の家族歴は腎症の発症や進行に関連するか。IgAにおいて血尿は腎機能予後に影響するか。P111-113, 2018、東京医学社
47. 鈴木　仁：IgA腎症の基礎知識　IgA腎症の進展機序をマーカーから考える．IgA腎症の臨床湯村和子編、2018年9月号、東京医学社, P11-17
48. 禾千絵子、鈴木　仁、鈴木祐介：IgA腎症の基礎知識　IgA腎症の発症機序から考える治療の妥当性．IgA腎症の臨床　湯村和子編、2018年9月号, 東京医学社, P2-7
49. 鈴木　仁、鈴木祐介：IgA腎症の新規分子標的治療薬の可能性．P187-190, IgA腎症の臨床　湯村和子編、2018年9月号, 東京医学社
50. 鈴木　仁、鈴木祐介：Tonsil induced autoimmune/inflammatory syndrome (TIAS) としてのIgA腎症．アレルギー・免疫、2018年6月号、25, P802-809, 医薬ジャーナル社
51. 鈴木　仁：IgA腎症-新規バイオマーカーを用いた早期診断と活動性評価．腎と透析86巻5号、2019年、東京医学社
52. 鈴木　仁、鈴木祐介：IgA腎症：発症要因と診断法、早期治療への展開．腎疾患・透析最新の治療2020-2022、2019年, 南江堂
53. 鈴木　仁、鈴木祐介：IgA腎症のエンドポイント．医学のあゆみ269巻7号、2019年、医歯薬出版
54. 鈴木　仁：バイオマーカー、免疫複合体の特徴と成因．IgA腎症の病態と治療．P93-96, 2019年、中外医学社

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

鈴木 仁（スズキ ヒトシ）

鈴木仁（スズキヒトシ）